Theriva Receives AEMPS Approval to Initiate VIRAGE2 Trial
Theriva Biologics obtained regulatory authorization from the Spanish Agency for the VIRAGE2 clinical trial testing increased VCN-01 dosing in metastatic pancreatic cancer. This study aims to optimize dosing frequency based on previous survival data.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
GET FREE KEY — 10,000 calls/day